<italic style="font-style: italic">Shengjie Tongyu Decoction</italic> （升解通瘀汤） Combined with Western Medicine for the Treatment of <italic style="font-style: italic">Qi</italic> Deficiency and Blood Stasis of Chronic Heart Failure caused by Ischemic cardiomyopathy： A Randomized Controlled Trial

SUN Ziyi; YAO Kuiwu; WANG Zihan; SHI Zaixiang; FAN Jiakun; YANG Dexiang; HUANG Li; LI Chunyan

doi:10.13288/j.11-2166/r.2023.07.008

您当前的位置：

首页 >

文章列表页 >

Shengjie Tongyu Decoction （升解通瘀汤） Combined with Western Medicine for the Treatment of Qi Deficiency and Blood Stasis of Chronic Heart Failure caused by Ischemic cardiomyopathy： A Randomized Controlled Trial

更新时间：2023-04-17

- Shengjie Tongyu Decoction （升解通瘀汤） Combined with Western Medicine for the Treatment of Qi Deficiency and Blood Stasis of Chronic Heart Failure caused by Ischemic cardiomyopathy： A Randomized Controlled Trial
- Journal of Traditional Chinese Medicine Vol. 64, Issue 7, Pages: 686-691(2023)
- 作者机构：
  
  1.北京中医药大学，北京市朝阳区北三环东路11号，100029
  2.中国中医科学院眼科医院
  3.中日友好医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2023.07.008
  CLC：
- Received：21 September 2022，
  
  Revised：2023-01-18，
  
  Published：02 April 2023
- 稿件说明：
移动端阅览
孙梓宜,姚魁武,王子涵等.升解通瘀汤联合常规西药治疗缺血性心肌病致慢性心力衰竭气虚血瘀证的随机对照研究[J].中医杂志,2023,64(07):686-691.

SUN Ziyi,YAO Kuiwu,WANG Zihan,et al.Shengjie Tongyu Decoction （升解通瘀汤） Combined with Western Medicine for the Treatment of Qi Deficiency and Blood Stasis of Chronic Heart Failure caused by Ischemic cardiomyopathy： A Randomized Controlled Trial[J].Journal of Traditional Chinese Medicine,2023,64(07):686-691.
孙梓宜,姚魁武,王子涵等.升解通瘀汤联合常规西药治疗缺血性心肌病致慢性心力衰竭气虚血瘀证的随机对照研究[J].中医杂志,2023,64(07):686-691. DOI： 10.13288/j.11-2166/r.2023.07.008.

SUN Ziyi,YAO Kuiwu,WANG Zihan,et al.Shengjie Tongyu Decoction （升解通瘀汤） Combined with Western Medicine for the Treatment of Qi Deficiency and Blood Stasis of Chronic Heart Failure caused by Ischemic cardiomyopathy： A Randomized Controlled Trial[J].Journal of Traditional Chinese Medicine,2023,64(07):686-691. DOI： 10.13288/j.11-2166/r.2023.07.008.

摘要

目的

评价升解通瘀汤联合西药治疗缺血性心肌病致慢性心力衰竭气虚血瘀证的疗效及安全性。

方法

60例缺血性心肌病致慢性心力衰竭气虚血瘀证患者随机分为治疗组和对照组各30例。对照组予常规西药治疗，治疗组在对照组基础上联合升解通瘀汤口服，每日1剂，两组疗程均为8周。分别于治疗前后检测两组患者的堪萨斯城心肌病问卷（KCCQ）积分、纽约心脏协会（NYHA）心功能分级、左室射血分数（LVEF）、6分钟步行试验（6MWT）、血清N端脑钠肽前体（NTpro-BNP）水平及中医证候积分，治疗后判定中医证候疗效并进行安全性评价。

结果

治疗组中医证候疗效总有效率为96.67%（29例/30例），对照组为50%（15例/30例），治疗组疗效优于对照组（

＜0.05）。与本组治疗前比较，治疗后两组患者KCCQ积分、NYHA心功能分级、中医证候积分、6MWT均明显改善，治疗组LVEF、血清NTpro-BNP水平亦明显改善（

＜0.05）；与对照组治疗后比较，治疗组KCCQ积分、NYHA心功能分级、LVEF、6MWT、中医证候积分差异均有统计学意义（

＜0.05），治疗组改善程度更佳。试验过程中对照组有6例患者、治疗组有1例患者因心力衰竭加重而入院，对照组发生不良事件8例，治疗组发生不良事件4例，经判断均与试验药物无关。

结论

在常规西药基础上联合升解通瘀汤治疗可改善缺血性心肌病致慢性心力衰竭气虚血瘀证患者的心功能、中医证候，提高运动耐量及生活质量，且安全性良好。

Abstract

Objective

To evaluate the effectiveness and safety of

Shengjie Tongyu Decoction

（升解通瘀汤， STD） in the treatment of chronic heart failure with

deficiency and blood stasis caused by ischemic cardiomyopathy.

Methods

A total of 60 patients with chronic heart failure with

deficiency and blood stasis caused by ischemic cardiomyopathy were randomly divided into the treatment and control groups with each group of 30 cases. The control group was treated with conventional western medicine， and the treatment group was treated with STD based on conventional western medicine with one dose daily in two divided doses. The duration of treatment for both groups was 8 weeks. The changes of Kansas City Cardiomyopathy Questionnaire score （KCCQ）， New York Heart Association （NYHA） cardiac function class， left ventricular ejection fraction （LVEF）， 6-minute walk test distance （6MWTD）， N-terminal brain natriuretic peptide precursor （NTpro-BNP） levels and Traditional Chinese Medicine （TCM） pattern score were detected before and after the treatment in the two groups， and the safety was evaluated.

Results

The total effectiveness of the treatment of the TCM pattern score of the treatment group was 96.67% （29/30 cases）， and the control group was 50% （15/30 cases）. The treatment group was better than the control group （

＜0.05）. Compared with those before treatment， the total KCCQ score， NYHA cardiac function classification， 6MWTD， and TCM pattern score improved in both groups after treatment （

＜0.05）； and the improvement in the treatment group was better than that in the control group （

＜0.05）. During the trial， six patients in the control group and one in the treatment group were admitted for heart failure exacerbation， and eight adverse events occurred in the control group and four in the treatment group， which were judged to be unrelated to the adverse effects of the experimental drug.

Conclusion

STD combined with conventional western medicine therapy can improve cardiac function， TCM pattern， exercise tolerance， and quality of life in patients with chronic heart failure due to

deficiency and blood stasis caused by ischemic cardiomyopathy with good safety.

关键词

Keywords

references

Task Force Members ， MONTALESCOT G ， SECHTEM U ， et al . 2013 esc guidelines on the management of stable co-ronary artery disease： the task force on the management of stable coronary artery disease of the european society of cardiology ［J］. Eur Heart J ， 2013 ， 34 （ 38 ）： 2949 - 3003 .

BUONO MGD ， MORONI F ， MONTONE RA ， et al . Ische-mic cardiomyopathy and heart failure after acute myocardial infarction ［J］. Curr Cardiol Rep ， 2022 ， 24 （ 10 ）： 1505 .

MAO J ， ZHANG J ， LAM CSP ， et al . Qishen Yiqi dripping pills for chronic ischaemic heart failure： results of the CACT-IHF randomized clinical trial ［J］. ESC Heart Fail ， 2020 ， 7 （ 6 ）： 3881 - 3890 .

LI X ， ZHANG J ， HUANG J ， et al . A multicenter， randomized， double-blind， parallel-group， placebo-controlled study of the effects of Qili Qiangxin capsules in patients with chronic heart failure ［J］. J Am Coll Cardiol ， 2013 ， 62 （ 12 ）： 1065 - 1072 .

潘光明，崔嘉妍，姚耿圳，等 . 升解通瘀汤颗粒治疗瘀血型难治性心绞痛的疗效分析［J］. 热带医学杂志， 2018 ， 18 （ 6 ）： 761 - 765 .

滕静 . 升解通瘀颗粒对不稳定型心绞痛的临床疗效及炎症因子的影响［D］. 北京：北京中医药大学， 2020 .

葛均波，徐永健，王辰 . 内科学［M］. 9版 . 北京：人民卫生出版社， 2018 ： 228 - 229 .

王华，梁延春 . 中国心力衰竭诊断和治疗指南2018 ［J］. 中华心血管病杂志， 2018 ， 46 （ 10 ）： 760 - 789 .

陈可冀，吴宗贵，朱明军，等 . 慢性心力衰竭中西医结合诊疗专家共识［J］. 中国中西医结合杂志， 2016 ， 36 （ 2 ）： 133 - 141 .

郑筱萸 . 中药新药临床研究指导原则（试行）［M］. 北京：中国医药科技出版社， 2002 ： 79 - 81 .

ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories . ATS statement： guidelines for the six-minute walk test ［J］. Am J Respir Crit Care Med ， 2002 ， 166 （ 1 ）： 111 - 117 .

LANCASTER GA ， DODD S ， WILLIAMSON PR . Design and analysis of pilot studies： recommendations for good practice ［J］. J Eval Clin Pract ， 2004 ， 10 （ 2 ）： 307 - 312 .

王斌，李毅，韩雅玲 . 稳定性冠心病诊断与治疗指南［J］. 中华心血管病杂志， 2018 ， 46 （ 9 ）： 680 - 694 .

GREEN CP ， PORTER CB ， BRESNAHAN DR ， et al . Development and evaluation of the kansas city cardiomyo-pathy questionnaire： a new health status measure for heart failure ［J］. J Am Coll Cardiol ， 2000 ， 35 （ 5 ）： 1245 - 1255 .

YANCY CW ， JESSUP M ， BOZKURT B ， et al . 2017 acc/aha/hfsa focused update of the 2013 accf/aha guideline for the management of heart failure： a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of america ［J］. Circulation ， 2017 ， 136 （ 6 ）： e137 - e161 .

戴超俊，李翠云，林超，等 . 缺血性心肌病患者中医证型、心功能、血清人可溶性生长刺激表达基因蛋白2水平的相关性［J］. 中医杂志， 2019 ， 60 （ 21 ）： 1827 - 1831 .

李春岩 . 史载祥学术思想及升陷祛瘀法治疗心血管疾病的理论及临床研究［D］. 北京：中国中医科学院， 2013 .

李春岩，史载祥 . 升解通瘀颗粒对稳定型心绞痛气陷血瘀证患者临床疗效及血脂的影响［J］. 中华中医药杂志， 2017 ， 32 （ 4 ）： 1534 - 1537 .

JOHANSSON I ， JOSEPH P ， BALASUBRAMANIAN K ， et al . Health-related quality of life and mortality in heart failure： the global congestive heart failure study of 23 000 patients from 40 countries ［J］. Circulation ， 2021 ， 143 （ 22 ）： 2129 - 2142 .

POKHAREL Y ， KHARITON Y ， TANG Y ， et al . Association of serial kansas city cardiomyopathy questionnaire assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction： a secondary analysis of 2 randomized clinical trials ［J］. JAMA Cardiol ， 2017 ， 2 （ 12 ）： 1315 - 1321 .

YEE D ， NOVAK E ， PLATTS A ， et al . Comparison of the kansas city cardiomyopathy questionnaire and minnesota living with heart failure questionnaire in predicting heart failure outcomes ［J］. Am J Cardiol ， 2019 ， 123 （ 5 ）： 807 - 812 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Shengjie Tongyu Decoction （升解通瘀汤） on Urine Metabolomics in Patients with Ischemic Cardiomyopathy-induced Chronic Heart Failure and Qi Deficiency and Blood Stasis Syndrome

Effect of Shenqi Jianxin Formula（参芪健心方）on Mitochondrial Autophagy and the PINK1/Parkin Signaling Pathway in Cardiac Tissues in Chronic Heart Failure

Effect of Optimized New Shengmai Powder （优化新生脉散方） on Exercise Tolerance in Patients with Chronic Heart Failure of Qi Deficiency，Blood Stasis and Fluid Retention Syndrome：A Randomized，Double-Blind，Placebo-Controlled Trial

Overview of Study on Syndromic Characteristics and Microscopic Indicators of Qi Deficiency and Blood Stasis Syndrome in Chronic Heart Failure

Effect of Shenfu Injection （参附注射液） on SIRT1 Deacetylation-modified Regulation of HMGB1/TLR4/NF-κB Pathway in Isoproterenol-induced Cardiomyocyte Injury Model

Related Author

SUN Ziyi

YAO Kuiwu

WANG Zihan

LIU Jingnan

FAN Jiarong

XIE Peichi

LIU Pan

DING Zitong

Related Institution

Beijing University of Chinese Medicine

Eye Hospital, China Academy of Chinese Medical Sciences

First Clinical Medical College，Anhui University of Chinese Medicine

College of Traditional Chinese Medicine，Anhui University of Chinese Medicine

The First Affiliated Hospital of Anhui University of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Shengjie Tongyu Decoction （升解通瘀汤） Combined with Western Medicine for the Treatment of Qi Deficiency and Blood Stasis of Chronic Heart Failure caused by Ischemic cardiomyopathy： A Randomized Controlled Trial

DOI：10.13288/j.11-2166/r.2023.07.008

摘要

Abstract

关键词

Keywords

references